For the third quarter, we reported a net loss attributable to common stockholders of $25.2 million or $0.73 per diluted share.
For the quarter, we reported AFFO per diluted share of $0.52, which represents a growth rate of 373% over the prior year quarter.
We ended the quarter with approximately $602 million of net working capital, which equates to approximately $17 per diluted share.
With yesterday's closing stock price of $7.88, we believe we are trading at a meaningful discount to both our net asset value per share and our net working capital per share.
We also ended the quarter with net working capital of approximately $602 million.
As we look ahead to 2023, we are currently expecting total CapEx spend between $100 million and $120 million.
As Rob mentioned, I think it's also important to point out that this net working capital amount of $602 million equates to approximately $17 per share.
In the third quarter, our weighted average fully diluted share count used to calculate AFFO per share included approximately 1.7 million common shares associated with the exit fee on the strategic financing we completed in January 2021.
This compares to our closing stock price from yesterday of $7.88, which is an approximate 54% discount to our net working capital per share.
For 2022, our CapEx spending is higher than the previous 2 years but will still be well below our historical run rate for CapEx.
We have [attended] numerous industry in Wall Street conferences, which have led to over 400 investor meetings year-to-date.
Our share count currently stands at approximately 36.2 million fully diluted shares outstanding, which is comprised of 34.5 million shares of common stock and 1.7 million OP units.
Our long-term group momentum shows encouraging signs, with group lead volume generated during the third quarter, exceeding the previous 2 quarters.
CapEx spend during the third quarter was approximately $25 million, and we currently anticipate strategically deploying approximately $100 million to $110 million in capital expenditures in 2022.
Adjusted EBITDAre was $82.1 million for the quarter, which reflected a growth rate of 75% over the prior year quarter.
I'm pleased to note that September was the best performing month of the third quarter, along with the best month we've had versus 2019 during this recovery, with RevPAR up [0.4%] versus 2019.